[News in the medical treatment of breast cancer].
During the last decade, except for breast cancer, few "solid" tumours have benefited from significant progress in systemic treatment able to reduce the progression of metastases in advanced disease or to eradicate possible micro-metastases in the adjuvant situation. This review aims to guide the reader along the paths of the progress made in hormonotherapy, chemotherapy and targeted molecular therapy. For each category, the authors will attempt to estimate the impact of the therapeutic advances upon day-to-day clinical practice.
Piccart
Martine
M
Unité de chimiothérapie, Institut Jules-Bordet, 1, rue Heger-Bordet, 1000 Bruxelles, Belgique.
Dochy
Emmanuelle
E
Cardoso
Fatima
F
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D013629:Tamoxifen / Q000627:therapeutic use; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D013629:Tamoxifen; D000068878:Trastuzumab